EpilepsyGTx lands €28M to test one-shot gene therapy for severe epilepsy
EpilepsyGTx has secured a €28 million Series A to push its lead gene therapy, EPY201, into Phase 1/2a trials. The treatment aims to stop seizures in severe epilepsy patients with a single, localized brain injection.